STAA

STAAR Surgical Co. 10-Q Summary: Quarter Ended March 31, 2006

Business Context and Reporting Period

This filing covers the quarterly period ended March 31, 2006. STAAR Surgical Company develops and manufactures visual implants and ophthalmic products, primarily for cataract and refractive surgery. The company operates globally with manufacturing sites in the United States and Switzerland. A key strategic focus for the period was the U.S. launch of the Visian ICL (Implantable Collamer Lens) following FDA approval in December 2005.

Key Financial Metrics

Cash Flow: Net cash used in operating activities was $3.11 million. Net cash used in investing activities was $0.43 million, primarily for property and equipment. Net cash provided by financing activities was $0.40 million, driven by stock option exercises.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 2.7% year-over-year. Excluding currency impacts, sales were flat to slightly up (1%).
• Product Mix Shift: ICL sales surged 73% to $2.36 million, now representing 18% of total sales. Conversely, core cataract product sales declined 12% to $10.67 million.
• Geographic Performance: U.S. sales increased 3.5%, driven by the ICL launch. International sales decreased 6.2%, impacted by currency fluctuations and doctor strikes in Germany.
• Expense Increases: Operating expenses rose significantly. General and Administrative (G&A) expenses increased 19%, and Research and Development (R&D) increased 34.5%. A significant portion of these increases ($0.41 million total) is attributable to the adoption of SFAS 123R (stock-based compensation).
• Liquidity: Cash balances decreased by $3.04 million during the quarter due to operating losses and capital expenditures.

Outlook, Risks, and Contingencies

• Guidance and Strategy: Management targets training approximately 500 surgeons for the ICL by the end of 2006. The company expects to maintain Days Sales Outstanding (DSO) between 40 and 45 days. Management does not expect positive consolidated cash flow for fiscal 2006.
• Legal Settlement: The company reached a settlement in a securities class action lawsuit regarding the Visian ICL approval timeline. The total consideration is $3.7 million, largely covered by insurance, with the company retaining approximately $100,000 in administrative costs and up to $500,000 in defense costs (already accrued).
• Regulatory Risks: The company is focused on maintaining FDA compliance following past warning letters. A Pre-Market Approval (PMA) application for the Visian Toric ICL (TICL) was submitted to the FDA on April 28, 2006.
• Market Risks: Sales in Germany were negatively affected by doctor strikes and government reimbursement cuts. Competition from multifocal IOLs in the U.S. remains a challenge for cataract product sales.
• Financing: The company signed a commitment letter for a $3.0 million revolving credit facility with Wells Fargo Bank (pending finalization) and is pursuing a $1.0 million lease line of credit.

Investor Verification Checklist

• ICL Adoption Rate: Verify the number of surgeons trained and actual U.S. ICL sales volume against the target of 500 surgeons by year-end.
• German Operations: Monitor the duration and impact of doctor strikes and reimbursement policy changes in Germany on international revenue.
• Cash Burn Rate: Assess the sustainability of the current cash position ($9.66 million) given the continued operating losses and negative operating cash flow.
• Debt Covenants: Confirm compliance with the Swiss credit facility covenants, specifically the minimum equity requirement of $12.0 million.
• Stock-Based Compensation: Review the impact of SFAS 123R on future earnings, noting $2.9 million of unrecognized compensation cost remaining.